Curated News
By: NewsRamp Editorial Staff
June 24, 2026

LakeShore Biopharma Goes Private in Merger with Oceanpine

Discuss on Substack
Original Source

TLDR

  • LakeShore Biopharma completed its going-private merger, offering shareholders $0.066 per share in cash.
  • The merger involved cancellation of shares for cash, followed by deregistration and suspension of SEC reporting obligations.
  • By going private, LakeShore Biopharma can focus on developing vaccines for infectious diseases and cancer.
  • Shares traded after the merger effective date will be invalid, as securities no longer exist.

Impact - Why it Matters

This transaction matters because it privatizes a key developer of vaccines and biologics targeting rabies, hepatitis B, and influenza, potentially accelerating its research and product development away from public market scrutiny. For shareholders, it provides a defined cash exit; for the industry, it highlights the growing trend of biopharma companies seeking private ownership to fund long-term innovation. The PIKA® platform's future could now be advanced with greater strategic flexibility, impacting global health solutions for infectious diseases.

Summary

LakeShore Biopharma Co., Ltd, a global biopharmaceutical company focused on vaccines and therapeutic biologics for infectious diseases and cancer, has announced the completion of its going-private merger with Oceanpine Skyline Inc. The merger, approved by shareholders on June 19, 2026, results in LakeShore becoming a wholly owned subsidiary of Oceanpine Skyline and ceasing to be a publicly traded company. Shareholders will receive US$0.066 per share in cash, with detailed instructions to follow via a letter of transmittal. The company intends to suspend its SEC reporting obligations by filing a Form 15, and its trading symbols are expected to be removed from the OTC Markets. The move marks a significant transition for LakeShore, which operates in China, Singapore, and the Philippines and is known for its proprietary PIKA® immunomodulating technology platform targeting Rabies, Hepatitis B, Influenza, and other viruses.

Key players in the transaction include the Special Committee of LakeShore's board, advised by Kroll, LLC as financial advisor and Gibson, Dunn & Crutcher LLP as U.S. legal counsel, with Maples and Calder (Hong Kong) LLP serving as Cayman Islands legal counsel. White & Case LLP represents the buyer group. The merger agreement was originally dated November 4, 2025, and amended in April 2026. The company warns that any trades after the merger's consummation but before FINRA removes the trading symbols will be invalid, and it will not be responsible for resulting losses. The completion of this transaction underscores LakeShore's strategic shift away from public markets, potentially allowing for more focused long-term investments in its vaccine pipeline.

The company's proprietary PIKA® platform has been a cornerstone of its innovation, and the going-private transaction may enable LakeShore to pursue its R&D goals without the quarterly pressures of public reporting. For investors, the merger provides a cash exit at a fixed price, while the company gains operational flexibility. The broader biopharmaceutical industry may watch this development as a case study in the trend of smaller biotechs opting for privatization to access capital and resources more efficiently. The original news release can be found on NEWMEDIAWIRE, with additional details at the company's investor relations page.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, LakeShore Biopharma Goes Private in Merger with Oceanpine

blockchain registration record for this content.